Skip to Main Content

CORE in the News

  • What to Know about Lipoprotein(a)

    Many patients receive a standardized lipid panel as part of a yearly physical that includes testing of their “good” cholesterol (high-density lipoprotein) and “bad” cholesterol (low-density lipoprotein). However, most people are unfamiliar with another type of cholesterol, lipoprotein(a) or Lp(a). This type of lipoprotein is not included in the standard lipid panel but is an independent risk factor for cardiovascular disease. In the following Q&A, Yale clinicians and researchers share background about Lp(a), guidance for caring for patients with elevated levels, and new approaches to improve testing.

    Read more
  • Yale CRRIT Researchers Examine Cancer Drug Guidelines and FDA Approvals

    Drugs for serious or life-threatening diseases can receive expedited U.S. Food and Drug Administration (FDA) review, allowing patients to receive faster access to promising new treatments. Under the expedited review pathway of accelerated approval, drugs can be FDA-approved based on surrogate markers or proxy measures such as changes in imaging or lab tests that are “reasonably likely” to predict whether patients improve in how they feel, function, or survive.

    Read more
  • Ranney, Opara to attend Aspen Ideas: Health conference

    YSPH Dean Megan L. Ranney, MD, and Ijeoma Opara, associate professor of social and behavioral sciences, are attending the Aspen Ideas: Health conference June 20-23 in Aspen, Colorado. Ranney will participate in three panel discussions; Opara is an Aspen Ideas: Health Fellow.

    Read more
Get RSS Feed